Last reviewed · How we verify

Ephedrine, bolus

University of Parma · FDA-approved active Small molecule Under review

Ephedrine, bolus is a Sympathomimetic amine; adrenergic agonist Small molecule drug developed by University of Parma. It is currently FDA-approved for Hypotension and shock (acute hemodynamic support), Bronchospasm and asthma exacerbation, Nasal congestion.

Ephedrine is a sympathomimetic amine that stimulates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial airway dilation.

Ephedrine is a small molecule adrenergic receptor agonist used in medical settings. It has been studied for various conditions, including post spinal hypotension, anesthesia, and acute kidney failure, as an intervention in clinical trials.

At a glance

Generic nameEphedrine, bolus
SponsorUniversity of Parma
Drug classSympathomimetic amine; adrenergic agonist
TargetAlpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
ModalitySmall molecule
Therapeutic areaCardiovascular; Respiratory
PhaseFDA-approved

Mechanism of action

Ephedrine acts as a direct and indirect adrenergic agonist, binding to alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. It increases norepinephrine release from nerve terminals and directly activates adrenergic receptors, resulting in increased cardiac output, peripheral vasoconstriction, and bronchodilation. The bolus formulation delivers rapid onset of action for acute hemodynamic support.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ephedrine, bolus

What is Ephedrine, bolus?

Ephedrine, bolus is a Sympathomimetic amine; adrenergic agonist drug developed by University of Parma, indicated for Hypotension and shock (acute hemodynamic support), Bronchospasm and asthma exacerbation, Nasal congestion.

How does Ephedrine, bolus work?

Ephedrine is a sympathomimetic amine that stimulates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial airway dilation.

What is Ephedrine, bolus used for?

Ephedrine, bolus is indicated for Hypotension and shock (acute hemodynamic support), Bronchospasm and asthma exacerbation, Nasal congestion.

Who makes Ephedrine, bolus?

Ephedrine, bolus is developed and marketed by University of Parma (see full University of Parma pipeline at /company/university-of-parma).

What drug class is Ephedrine, bolus in?

Ephedrine, bolus belongs to the Sympathomimetic amine; adrenergic agonist class. See all Sympathomimetic amine; adrenergic agonist drugs at /class/sympathomimetic-amine-adrenergic-agonist.

What development phase is Ephedrine, bolus in?

Ephedrine, bolus is FDA-approved (marketed).

What are the side effects of Ephedrine, bolus?

Common side effects of Ephedrine, bolus include Tachycardia, Hypertension, Tremor, Anxiety and nervousness, Insomnia, Headache.

What does Ephedrine, bolus target?

Ephedrine, bolus targets Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors and is a Sympathomimetic amine; adrenergic agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing